Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer
Status:
Completed
Trial end date:
2019-12-27
Target enrollment:
Participant gender:
Summary
This is a prospective, open-label, single arm translational study of cabazitaxel in bone
Castration Resistant metastatic Pancreatic Cancer (mCRPC) patients. Patient will be treated
with intravenous (iv) cabazitaxel 25mg/m2 every (q) 21days per standard clinical practice for
up to 10 cycles or until disease progression or unacceptable toxicity or physician's decision
or patient's consent withdrawal (whichever occurs first).